Michael Barbella, Managing Editor11.30.23
NanoVibronix Inc.'s application for UroShield actuators to be available on NHS Prescription Services’ Drug Tariff has been approved. In addition, the company has extended its contract by four years with NHS Supply Chain for UroShield supplies (through its U.K. distribution partner, Peak Medical Limited).
Drug Tariff enables the NHS to fully reimburse providers for UroShield actuators. U.K. hospital and community clinicians can now prescribe UroShield either through the prescription process or through the NHS contract, relieving patients of cost responsibilities.
“Receiving reimbursement approval is a vitally important advancement in our efforts to increase access to and distribution of UroShield. Approval for clinicians to prescribe alongside the NHS procurement contract greatly eases a patient’s ability to access the UroShield device through their healthcare providers, wherever they are being treated. Across the health system, the cost of UroShield actuators will no longer be a limiting factor for patients," NanoVibronix CEO Brian Murphy said. "We are pleased the NHS recognizes the value of the UroShield technology and the patient benefits that the device can deliver, whilst also addressing the resource and financial challenges in the healthcare system. Achieving reimbursement status had been a critical missing piece to advancing distribution in the NHS and now with this hurdle cleared, we are better positioned to increase unit sales throughout the country. Through our partnership with Peak Medical Limited, we have an established distribution channel and a robust team of sales and marketing professionals with vast experience in urological medicine. Furthermore, we are increasing production to meet the upsurge in demand that we believe will be generated from this new development.”
“With the Drug Tariff listing, healthcare professionals now have the option of prescribing UroShield actuators to help prevent catheter-associated urinary tract infections (C-AUTIs) for patients with indwelling catheters. At Peak Medical, we are committed to delivering products that can have a positive impact on patient outcomes, and UroShield has been proven and recognized by the NHS as an effective solution for preventing infection," Peak Medical Managing Director Auriol Lawson stated. "We are delighted to be working with NanoVibronix to increase product awareness and channel the preventative devices to all patients who will benefit from its use.”
NanoVibronix Inc. is a medical device company headquartered in Elmsford, N.Y., with R&D in Nesher, Israel, focused on developing medical devices using its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety to medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The company’s primary products include PainShield and UroShield, which are portable devices suitable for administration at home without assistance of medical professionals.
Drug Tariff enables the NHS to fully reimburse providers for UroShield actuators. U.K. hospital and community clinicians can now prescribe UroShield either through the prescription process or through the NHS contract, relieving patients of cost responsibilities.
“Receiving reimbursement approval is a vitally important advancement in our efforts to increase access to and distribution of UroShield. Approval for clinicians to prescribe alongside the NHS procurement contract greatly eases a patient’s ability to access the UroShield device through their healthcare providers, wherever they are being treated. Across the health system, the cost of UroShield actuators will no longer be a limiting factor for patients," NanoVibronix CEO Brian Murphy said. "We are pleased the NHS recognizes the value of the UroShield technology and the patient benefits that the device can deliver, whilst also addressing the resource and financial challenges in the healthcare system. Achieving reimbursement status had been a critical missing piece to advancing distribution in the NHS and now with this hurdle cleared, we are better positioned to increase unit sales throughout the country. Through our partnership with Peak Medical Limited, we have an established distribution channel and a robust team of sales and marketing professionals with vast experience in urological medicine. Furthermore, we are increasing production to meet the upsurge in demand that we believe will be generated from this new development.”
“With the Drug Tariff listing, healthcare professionals now have the option of prescribing UroShield actuators to help prevent catheter-associated urinary tract infections (C-AUTIs) for patients with indwelling catheters. At Peak Medical, we are committed to delivering products that can have a positive impact on patient outcomes, and UroShield has been proven and recognized by the NHS as an effective solution for preventing infection," Peak Medical Managing Director Auriol Lawson stated. "We are delighted to be working with NanoVibronix to increase product awareness and channel the preventative devices to all patients who will benefit from its use.”
NanoVibronix Inc. is a medical device company headquartered in Elmsford, N.Y., with R&D in Nesher, Israel, focused on developing medical devices using its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety to medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The company’s primary products include PainShield and UroShield, which are portable devices suitable for administration at home without assistance of medical professionals.